97 related articles for article (PubMed ID: 23677930)
1. ERα-targeted therapy in ovarian cancer cells by a novel estradiol-platinum(II) hybrid.
Brasseur K; Leblanc V; Fabi F; Parent S; Descôteaux C; Bérubé G; Asselin E
Endocrinology; 2013 Jul; 154(7):2281-95. PubMed ID: 23677930
[TBL] [Abstract][Full Text] [Related]
2. VP-128, a novel oestradiol-platinum(II) hybrid with selective anti-tumour activity towards hormone-dependent breast cancer cells in vivo.
Van Themsche C; Parent S; Leblanc V; Descôteaux C; Simard AM; Bérubé G; Asselin E
Endocr Relat Cancer; 2009 Dec; 16(4):1185-95. PubMed ID: 19661132
[TBL] [Abstract][Full Text] [Related]
3. Activation of estrogen receptor α by estradiol and cisplatin induces platinum-resistance in ovarian cancer cells.
Matsumura S; Ohta T; Yamanouchi K; Liu Z; Sudo T; Kojimahara T; Seino M; Narumi M; Tsutsumi S; Takahashi T; Takahashi K; Kurachi H; Nagase S
Cancer Biol Ther; 2017 Sep; 18(9):730-739. PubMed ID: 27689466
[TBL] [Abstract][Full Text] [Related]
4. Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17 β-estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor α and insulin-like growth factor-1 receptor signaling pathways.
Hwang KA; Park MA; Kang NH; Yi BR; Hyun SH; Jeung EB; Choi KC
Toxicol Appl Pharmacol; 2013 Nov; 272(3):637-46. PubMed ID: 23933164
[TBL] [Abstract][Full Text] [Related]
5. Biological evaluation of novel estrogen-platinum(II) hybrid molecules on uterine and ovarian cancers-molecular modeling studies.
Gagnon V; St-Germain ME; Descôteaux C; Provencher-Mandeville J; Parent S; Mandal SK; Asselin E; Bérubé G
Bioorg Med Chem Lett; 2004 Dec; 14(23):5919-24. PubMed ID: 15501069
[TBL] [Abstract][Full Text] [Related]
6. TR3 modulates platinum resistance in ovarian cancer.
Wilson AJ; Liu AY; Roland J; Adebayo OB; Fletcher SA; Slaughter JC; Saskowski J; Crispens MA; Jones HW; James S; Fadare O; Khabele D
Cancer Res; 2013 Aug; 73(15):4758-69. PubMed ID: 23720056
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, antiproliferative activity and estrogen receptor α affinity of novel estradiol-linked platinum(II) complex analogs to carboplatin and oxaliplatin. Potential vector complexes to target estrogen-dependent tissues.
Saha P; Descôteaux C; Brasseur K; Fortin S; Leblanc V; Parent S; Asselin E; Bérubé G
Eur J Med Chem; 2012 Feb; 48():385-90. PubMed ID: 22209414
[TBL] [Abstract][Full Text] [Related]
8. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
9. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
Chen J; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):285-92. PubMed ID: 27116987
[TBL] [Abstract][Full Text] [Related]
10. Targeting estrogen receptor subtypes (ERα and ERβ) with selective ER modulators in ovarian cancer.
Chan KK; Leung TH; Chan DW; Wei N; Lau GT; Liu SS; Siu MK; Ngan HY
J Endocrinol; 2014 May; 221(2):325-36. PubMed ID: 24819599
[TBL] [Abstract][Full Text] [Related]
11. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
12. Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma.
Hou JY; Rodriguez-Gabin A; Samaraweera L; Hazan R; Goldberg GL; Horwitz SB; McDaid HM
PLoS One; 2013; 8(2):e54103. PubMed ID: 23390495
[TBL] [Abstract][Full Text] [Related]
13. Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers.
Ciucci A; Zannoni GF; Buttarelli M; Lisi L; Travaglia D; Martinelli E; Scambia G; Gallo D
Oncotarget; 2016 Feb; 7(7):8155-71. PubMed ID: 26797759
[TBL] [Abstract][Full Text] [Related]
14. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment.
Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235
[TBL] [Abstract][Full Text] [Related]
15. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells.
Albanito L; Madeo A; Lappano R; Vivacqua A; Rago V; Carpino A; Oprea TI; Prossnitz ER; Musti AM; Andò S; Maggiolini M
Cancer Res; 2007 Feb; 67(4):1859-66. PubMed ID: 17308128
[TBL] [Abstract][Full Text] [Related]
16. Oestrogen receptor α mediates 17β-estradiol enhancement of ovarian cancer cell motility through up-regulation of survivin expression.
Zhu J; Lu X; Hua KQ; Sun H; Yu YH; Feng YJ
Arch Gynecol Obstet; 2012 Sep; 286(3):729-37. PubMed ID: 22569715
[TBL] [Abstract][Full Text] [Related]
17. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
Sui M; Jiang D; Hinsch C; Fan W
Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
[TBL] [Abstract][Full Text] [Related]
18. Estrous cycle modulates ovarian carcinoma growth.
Armaiz-Pena GN; Mangala LS; Spannuth WA; Lin YG; Jennings NB; Nick AM; Langley RR; Schmandt R; Lutgendorf SK; Cole SW; Sood AK
Clin Cancer Res; 2009 May; 15(9):2971-8. PubMed ID: 19383821
[TBL] [Abstract][Full Text] [Related]
19. JS-K, a nitric oxide donor, induces autophagy as a complementary mechanism inhibiting ovarian cancer.
Liu B; Huang X; Li Y; Liao W; Li M; Liu Y; He R; Feng D; Zhu R; Kurihara H
BMC Cancer; 2019 Jul; 19(1):645. PubMed ID: 31262254
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol regulates the cell viability promoted by 17β-estradiol or bisphenol A via down-regulation of the cross-talk between estrogen receptor α and insulin growth factor-1 receptor in BG-1 ovarian cancer cells.
Kang NH; Hwang KA; Lee HR; Choi DW; Choi KC
Food Chem Toxicol; 2013 Sep; 59():373-9. PubMed ID: 23810794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
